Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01194960 · ClinicalTrials.gov registry record · Phase 2
TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)
A Phase 2 study, sponsored by Oxford BioMedica.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT01194960: Clinical Trial Phase 2 study, sponsored by Oxford BioMedica.
NCT01194960 is a Phase 2 study that was terminated before completion, run by Oxford BioMedica. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01194960, a Phase 2 study, was terminated before completion, sponsored by Oxford BioMedica.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination therapy of TroVax® plus Docetaxel vs. Docetaxel alone on the progression free survival (PFS) of subjects with HRPC.
Primary Outcome
To establish whether the incidence of progression-free survival (as defined by the absence of progression assessed by both RECIST and PCWG2 criteria) at week 37 in the TroVax® plus Docetaxel treatment arm is higher than the incidence in the Docetaxel alone treatment arm.
Interventions
- DRUG Docetaxel
- DRUG TroVax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2010-08 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Why NCT01194960 stopped before completion
NCT01194960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 2 interventions - of which Docetaxel is the first listed.
NCT01194960 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01194960 about?
NCT01194960 is a clinical study titled "TroVax® In Subjects With Hormone Refractory Prostate Cancer (HRPC)". Based on both pre-clinical and clinical data, it may be advantageous to administer a cancer vaccine before chemotherapy to enhance immune responses, thus leading to a more effective therapeutic approach for subjects with metastatic HRPC. This clinical study will evaluate the role of combination ther...
What is the current status of trial NCT01194960?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2010-08. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01194960?
The interventions under investigation include: Docetaxel (DRUG), TroVax (DRUG).
Who is sponsoring clinical trial NCT01194960?
This trial is sponsored by Oxford BioMedica, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01194960's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia